HMGB1, anti-HMGB1 antibodies, and ratio of HMGB1/anti-HMGB1 antibodies as diagnosis indicator in fever of unknown origin

Abstract To evaluate the feasibility of serum HMGB1, anti-HMGB1 antibodies, and HMGB1/anti-HMGB1 ratio as a diagnosis indicator of initial clinical classification in patients with fever of unknown origin (FUO). Ninety-four patients with classical FUO and ninety healthy controls were enrolled in this...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mingkun Chen, Li Zhu, Miao Xue, Rongrong Zhu, Liling Jing, Huaizhou Wang, Yanghua Qin
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7a0959dbf066424b91e100631227e561
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7a0959dbf066424b91e100631227e561
record_format	dspace
spelling	oai:doaj.org-article:7a0959dbf066424b91e100631227e5612021-12-02T13:19:21ZHMGB1, anti-HMGB1 antibodies, and ratio of HMGB1/anti-HMGB1 antibodies as diagnosis indicator in fever of unknown origin10.1038/s41598-021-84477-22045-2322https://doaj.org/article/7a0959dbf066424b91e100631227e5612021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84477-2https://doaj.org/toc/2045-2322Abstract To evaluate the feasibility of serum HMGB1, anti-HMGB1 antibodies, and HMGB1/anti-HMGB1 ratio as a diagnosis indicator of initial clinical classification in patients with fever of unknown origin (FUO). Ninety-four patients with classical FUO and ninety healthy controls were enrolled in this study. The subjects’ clinical data and serum were collected. The serum concentration of HMGB1 was detected by a commercial HMGB1 ELISA kit, while the serum concentration of anti-HMGB1 antibodies were detected by an in-house built anti-HMGB1 antibodies ELISA kit and further confirmed by immunoblotting. According to the hospital diagnosis on discharge, ninety-four FUO patients were divided into four groups, Infectious disease subgroup, autoimmune disease subgroup, malignant tumor subgroup, and undetermined subgroup. The concentrations of HMGB1 in the infectious disease subgroup and autoimmune disease subgroup were higher than those in the malignant tumor subgroup, undetermined subgroup, and healthy control group. The concentration of anti-HMGB1 antibodies in autoimmune disease subtype group was higher than those in other subgroups as well as healthy control group. According to the distribution of HMGB1 and anti-HMGB1 in scatter plots of the patients with FUO, we found that the ratio of serum HMGB1/anti-HMGB1 is an ideal clinical indicator for differential diagnosis of different subtypes of FUO. The best cut-off was 0.75, and the sensitivity, specificity, and AUC were 66.67%, 87.32%, and 0.8, respectively. Correlation analysis showed that serum concentration of HMGB1 was moderately correlated with CRP in infectious diseases subgroup, and the serum concentration of anti-HMGB1 antibodies was strongly correlated with erythrocyte sedimentation rate in autoimmune disease subgroup. Our study had showed that serum HMGB1/anti-HMGB1 antibodies ratio can help clinicians identify FUO subtypes, thereby avoiding many unnecessary examinations and tests, and improving the effectiveness of clinical diagnosis and treatment of FUO.Mingkun ChenLi ZhuMiao XueRongrong ZhuLiling JingHuaizhou WangYanghua QinNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Mingkun Chen Li Zhu Miao Xue Rongrong Zhu Liling Jing Huaizhou Wang Yanghua Qin HMGB1, anti-HMGB1 antibodies, and ratio of HMGB1/anti-HMGB1 antibodies as diagnosis indicator in fever of unknown origin
description	Abstract To evaluate the feasibility of serum HMGB1, anti-HMGB1 antibodies, and HMGB1/anti-HMGB1 ratio as a diagnosis indicator of initial clinical classification in patients with fever of unknown origin (FUO). Ninety-four patients with classical FUO and ninety healthy controls were enrolled in this study. The subjects’ clinical data and serum were collected. The serum concentration of HMGB1 was detected by a commercial HMGB1 ELISA kit, while the serum concentration of anti-HMGB1 antibodies were detected by an in-house built anti-HMGB1 antibodies ELISA kit and further confirmed by immunoblotting. According to the hospital diagnosis on discharge, ninety-four FUO patients were divided into four groups, Infectious disease subgroup, autoimmune disease subgroup, malignant tumor subgroup, and undetermined subgroup. The concentrations of HMGB1 in the infectious disease subgroup and autoimmune disease subgroup were higher than those in the malignant tumor subgroup, undetermined subgroup, and healthy control group. The concentration of anti-HMGB1 antibodies in autoimmune disease subtype group was higher than those in other subgroups as well as healthy control group. According to the distribution of HMGB1 and anti-HMGB1 in scatter plots of the patients with FUO, we found that the ratio of serum HMGB1/anti-HMGB1 is an ideal clinical indicator for differential diagnosis of different subtypes of FUO. The best cut-off was 0.75, and the sensitivity, specificity, and AUC were 66.67%, 87.32%, and 0.8, respectively. Correlation analysis showed that serum concentration of HMGB1 was moderately correlated with CRP in infectious diseases subgroup, and the serum concentration of anti-HMGB1 antibodies was strongly correlated with erythrocyte sedimentation rate in autoimmune disease subgroup. Our study had showed that serum HMGB1/anti-HMGB1 antibodies ratio can help clinicians identify FUO subtypes, thereby avoiding many unnecessary examinations and tests, and improving the effectiveness of clinical diagnosis and treatment of FUO.
format	article
author	Mingkun Chen Li Zhu Miao Xue Rongrong Zhu Liling Jing Huaizhou Wang Yanghua Qin
author_facet	Mingkun Chen Li Zhu Miao Xue Rongrong Zhu Liling Jing Huaizhou Wang Yanghua Qin
author_sort	Mingkun Chen
title	HMGB1, anti-HMGB1 antibodies, and ratio of HMGB1/anti-HMGB1 antibodies as diagnosis indicator in fever of unknown origin
title_short	HMGB1, anti-HMGB1 antibodies, and ratio of HMGB1/anti-HMGB1 antibodies as diagnosis indicator in fever of unknown origin
title_full	HMGB1, anti-HMGB1 antibodies, and ratio of HMGB1/anti-HMGB1 antibodies as diagnosis indicator in fever of unknown origin
title_fullStr	HMGB1, anti-HMGB1 antibodies, and ratio of HMGB1/anti-HMGB1 antibodies as diagnosis indicator in fever of unknown origin
title_full_unstemmed	HMGB1, anti-HMGB1 antibodies, and ratio of HMGB1/anti-HMGB1 antibodies as diagnosis indicator in fever of unknown origin
title_sort	hmgb1, anti-hmgb1 antibodies, and ratio of hmgb1/anti-hmgb1 antibodies as diagnosis indicator in fever of unknown origin
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/7a0959dbf066424b91e100631227e561
work_keys_str_mv	AT mingkunchen hmgb1antihmgb1antibodiesandratioofhmgb1antihmgb1antibodiesasdiagnosisindicatorinfeverofunknownorigin AT lizhu hmgb1antihmgb1antibodiesandratioofhmgb1antihmgb1antibodiesasdiagnosisindicatorinfeverofunknownorigin AT miaoxue hmgb1antihmgb1antibodiesandratioofhmgb1antihmgb1antibodiesasdiagnosisindicatorinfeverofunknownorigin AT rongrongzhu hmgb1antihmgb1antibodiesandratioofhmgb1antihmgb1antibodiesasdiagnosisindicatorinfeverofunknownorigin AT lilingjing hmgb1antihmgb1antibodiesandratioofhmgb1antihmgb1antibodiesasdiagnosisindicatorinfeverofunknownorigin AT huaizhouwang hmgb1antihmgb1antibodiesandratioofhmgb1antihmgb1antibodiesasdiagnosisindicatorinfeverofunknownorigin AT yanghuaqin hmgb1antihmgb1antibodiesandratioofhmgb1antihmgb1antibodiesasdiagnosisindicatorinfeverofunknownorigin
_version_	1718393281525579776

HMGB1, anti-HMGB1 antibodies, and ratio of HMGB1/anti-HMGB1 antibodies as diagnosis indicator in fever of unknown origin

Ejemplares similares